The incidence of high-grade prostatic intraepithelial neoplasia and atypical glands suspicious for carcinoma on first-time saturation needle biopsy, and the subsequent risk of cancer
- PMID: 17233800
- DOI: 10.1111/j.1464-410X.2006.06728.x
The incidence of high-grade prostatic intraepithelial neoplasia and atypical glands suspicious for carcinoma on first-time saturation needle biopsy, and the subsequent risk of cancer
Abstract
Objective: To investigate the detection rate and extent of high-grade prostatic intraepithelial neoplasia (HGPIN) and atypical glands (AG) suspicious for prostate cancer, and the cancer risk in subsequent biopsies, diagnosed by a first 24-core saturation biopsy, as although the optimum extent of biopsy is controversial there is a trend to increase the number of cores taken, and apart from detecting prostate cancer, identifying HGPIN and AG is associated with a greater risk of finding cancer in subsequent biopsies, thus warranting a closer follow-up.
Patients and methods: The study included 100 men with consecutive first-time saturation biopsies; the indications for biopsy were an abnormal digital rectal examination and/or a serum prostate-specific antigen (PSA) level of >2.5 ng/mL. Each biopsy specimen was reviewed retrospectively by two pathologists to confirm the histological diagnosis. The number and percentage of cores positive for HGPIN, bilateral involvement and multifocality (HGPIN involving two or more cores) were recorded in each case. The presence of AG and cancer was also recorded. An extended (10-12 cores) repeat biopsy was available in 23 patients.
Results: The median (range) age and PSA level of the patients was 63 (41-80) years and 4.9 (1.5-67.0) ng/mL, respectively. Of the 100 patients, 34% had normal findings (benign prostatic tissue, BPT), 39% had cancer, 26% had HGPIN and cancer, 22% had HGPIN alone, and 5% had AG. Repeat biopsies were available in nine of the 22 (41%) patients with HGPIN, four of five with AG, and 10 of the 34 (29%) with BPT. The median (range) interval between the first and second biopsy was 13 (4-36) months. Prostate cancer was detected at the second biopsy in a third of patients with isolated HGPIN on the first biopsy, and one of the four with AG. None of the patients with BPT had cancer on re-biopsy. The cancer detection rate was significantly greater in patients with multifocal than in those with unifocal HGPIN (80% vs none, P = 0.010). The median number of cores and percentage of tissue involved by HGPIN was 3.5 (2-5) and 1.0 (0.5-1.2)%, respectively, in patients with cancer detected in repeat biopsies, compared to 1.0 (1-3) and 0.2 (0.2-0.6)% in patients without cancer on repeat biopsy (P = 0.023 and 0.015, respectively).
Conclusion: Identifying multifocal HGPIN on first saturation biopsy is associated with an overall cancer detection rate of 80% on repeat 10-12-core biopsy. Although there were few patients, the detection of multifocal HGPIN warrants additional searches for concurrent invasive carcinoma by repeated biopsy.
Similar articles
-
The proportion of cores with high-grade prostatic intraepithelial neoplasia on extended-pattern needle biopsy is significantly associated with prostate cancer on site-directed repeat biopsy.BJU Int. 2007 Apr;99(4):765-9. doi: 10.1111/j.1464-410X.2006.06681.x. BJU Int. 2007. PMID: 17378840
-
Predictors of prostate cancer on extended biopsy in patients with high-grade prostatic intraepithelial neoplasia: a multivariate analysis model.BJU Int. 2004 Sep;94(4):528-33. doi: 10.1111/j.1464-410X.2004.04996.x. BJU Int. 2004. PMID: 15329106
-
Prostate needle biopsies containing prostatic intraepithelial neoplasia or atypical foci suspicious for carcinoma: implications for patient care.J Urol. 2006 Mar;175(3 Pt 1):820-34. doi: 10.1016/S0022-5347(05)00337-X. J Urol. 2006. PMID: 16469560 Review.
-
Widespread high-grade prostatic intraepithelial neoplasia on prostatic needle biopsy: a significant likelihood of subsequently diagnosed adenocarcinoma.Am J Surg Pathol. 2006 Sep;30(9):1184-8. doi: 10.1097/01.pas.0000213324.97294.54. Am J Surg Pathol. 2006. PMID: 16931964
-
Prostate biopsy: who, how and when. An update.Can J Urol. 2005 Feb;12 Suppl 1:44-8; discussion 99-100. Can J Urol. 2005. PMID: 15780165 Review.
Cited by
-
Deregulation of FoxO3a accelerates prostate cancer progression in TRAMP mice.Prostate. 2013 Oct;73(14):1507-17. doi: 10.1002/pros.22698. Epub 2013 Jun 13. Prostate. 2013. PMID: 23765843 Free PMC article.
-
Management of rising prostate-specific antigen after a negative biopsy.Curr Urol Rep. 2011 Jun;12(3):197-202. doi: 10.1007/s11934-011-0177-1. Curr Urol Rep. 2011. PMID: 21344195 Review.
-
Precursor lesions to prostatic adenocarcinoma.Virchows Arch. 2009 Jan;454(1):1-16. doi: 10.1007/s00428-008-0707-5. Epub 2008 Dec 2. Virchows Arch. 2009. PMID: 19048290 Review.
-
Risks of testosterone replacement therapy in men.Indian J Urol. 2014 Jan;30(1):2-7. doi: 10.4103/0970-1591.124197. Indian J Urol. 2014. PMID: 24497673 Free PMC article. Review.
-
Risk of prostate cancer after detection of isolated high-grade prostatic intraepithelial neoplasia (HGPIN) on extended core needle biopsy: a UK hospital experience.BMC Urol. 2009 May 27;9:3. doi: 10.1186/1471-2490-9-3. BMC Urol. 2009. PMID: 19473479 Free PMC article.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials
Miscellaneous